OMTX705-006 Phase 1b

2025-521872-69-00 Protocol OMTX705-006 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 28 Oct 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 6 sites · Protocol OMTX705-006

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 63
Countries 1
Sites 6

Advanced/Metastatic Pancreatic Adenocarcinoma

Key facts

Sponsor
Oncomatryx Biopharma S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
28 Oct 2025 → ongoing
Decision date (initial)
2025-09-01
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced/Metastatic Pancreatic Adenocarcinoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Oncomatryx Biopharma S.A.

Sponsor organisation
Oncomatryx Biopharma S.A.
Address
Parque Tecnologico De Bizkaia 801b 2p
City
Derio
Postcode
48160
Country
Spain

Scientific contact point

Organisation
Oncomatryx Biopharma S.L.
Contact name
Ignacio Garcia-Ribas

Public contact point

Organisation
Oncomatryx Biopharma S.L.
Contact name
Ignacio Garcia-Ribas

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 54 6
Rest of world
United States
9

Investigational sites

Spain

6 sites · Ongoing, recruiting
Hospital Universitario Donostia
Oncology, Pasealeku Doct. Begiristain 109, 20014, Donostia
Complexo Hospitalario Universitario De Santiago
Oncology, Calle Choupana Da S/n, 15706, Santiago De Compostela
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario 12 De Octubre
Oncology, Avenida De Cordoba Sn, 28041, Madrid
Clinica Universidad De Navarra
Oncology, Pio XII Etorbidea 36, 31008, Pamplona
Institut Catala D'oncologia
Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-10-28 2025-10-28

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-06-12 Spain Acceptable
2025-08-20
2025-09-01
2 SUBSTANTIAL MODIFICATION SM-1 2025-10-01 Spain Acceptable 2025-10-24
3 NON SUBSTANTIAL MODIFICATION NSM-1 2026-01-28 Spain Acceptable 2026-01-28
4 SUBSTANTIAL MODIFICATION SM-2 2026-02-02 Spain Acceptable 2026-02-11